PXL065
Non-alcoholic steatohepatitis (NASH)
Phase 2Active
Key Facts
About Poxel
Poxel is a French biotech focused on developing first-in-class treatments for metabolic diseases by targeting mitochondrial bioenergetics. Its strategy leverages two core platforms—direct AMPK activation and optimized thiazolidinediones (TZDs)—to build a pipeline led by mid-stage NASH candidates PXL065 and PXL770. The company has transitioned to a revenue-generating entity through royalties from its partnered drug, Imeglimin, in Japan, but operates under a court-validated financial recovery plan, highlighting significant capital constraints alongside its clinical progress.
View full company profileOther Non-alcoholic steatohepatitis (NASH) Drugs
| Drug | Company | Phase |
|---|---|---|
| ADI-PEG 20 (pegargiminase) | Polaris Pharma | Phase 2 |
| Saroglitazar (Lipaglyn/Magdrop) | Zydus Lifesciences | Phase 3 |
| ORMD-0801 | Oramed Pharmaceuticals | Phase 2 |